{
    "key_points": [
        "WHO listed the Sinopharm COVID-19 vaccine for emergency use.",
        "Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of CNBG.",
        "WHO urges Sinopharm to participate in the COVAX Facility for more equitable vaccine distribution.",
        "The WHO's Emergency Use Listing (EUL) allows for expedited regulatory approval in various countries.",
        "The Sinopharm vaccine's assessment included on-site inspections of the production facility.",
        "The vaccine is suitable for adults 18 years and older, with a two-dose schedule.",
        "No upper age limit recommended for Sinopharm vaccine as it is likely to be effective in older adults.",
        "WHO recommends monitoring safety and effectiveness in older age groups using the vaccine.",
        "EUL procedure assesses novel health products during emergencies, focusing on safety, efficacy, and quality.",
        "Other vaccines listed for emergency use by WHO include Pfizer/BioNTech, AstraZeneca/Oxford, Janssen, and Moderna."
    ],
    "spokespersons": [
        "Dr Mari\u00e2ngela Sim\u00e3o (Assistant-Director General for Access to Health Products, WHO)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}